Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico [0.03%]
以墨西哥为例的医药创新壁垒——以抗癌药物为中心
Alfonso Duenas-Gonzalez,Aurora Gonzalez-Fierro
Alfonso Duenas-Gonzalez
Drug innovation does not only generate economic growth but also portrays a country's efforts toward innovation. The article reviews the current status on the innovation of the Mexican pharmaceutical industry with a focus on cancer drugs. Th...
Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice [0.03%]
临床试验中的估量选择：实施ICH E9(R1)指导原则
Bohdana Ratitch,James Bell,Craig Mallinckrodt et al.
Bohdana Ratitch et al.
The National Research Council (NRC) Expert Panel Report on Prevention and Treatment of Missing Data in Clinical Trials highlighted the need for clearly defining objectives and estimands. That report sparked considerable discussion and liter...
Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice [0.03%]
临床试验中的估量选择：实施ICH E9（R1）规范
Bohdana Ratitch,James Bell,Craig Mallinckrodt et al.
Bohdana Ratitch et al.
The National Research Council (NRC) Expert Panel Report on Prevention and Treatment of Missing Data in Clinical Trials highlighted the need for clearly defining objectives and estimands. That report sparked considerable discussion and liter...
Nancy A Dreyer,Marni Hall,Jennifer B Christian
Nancy A Dreyer
The Competence and Willingness to Consent to Research Among Patients with Heroin Dependence [0.03%]
海洛因依赖患者的研究同意能力及意愿
Liyan Zhao,Hong Shi,Bing Ying et al.
Liyan Zhao et al.
Background: Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to rese...
Correction to: A Comprehensive Analysis of Postmarket Surveillance Study Orders: Device Characteristics, Study Statuses, Outcomes, and Potential Contributions [0.03%]
对postmarket surveillance研究订单的综合分析的更正：设备特征、研究状态、结果及潜在贡献
Chie Iwaishi,Kiyotaka Iwasaki
Chie Iwaishi
In the original article Fig. 3 is not displayed correctly. The corrected figure follows.
Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan [0.03%]
日本临床试验中多重终点的多重性调整与样本量计算：现状调查
Kentaro Sakamaki,Yusuke Morita,Katsuhiro Iba et al.
Kentaro Sakamaki et al.
Background: Two issues in clinical trials with multiple endpoints were surveyed: (1) the terminology of multiple endpoints, the relationship between rare events and endpoints, and the differences in multiplicity adjustmen...
Patients' Perspectives of the Pharmaceutical Regulatory and Reimbursement Systems in Istanbul, Turkey [0.03%]
土耳其伊斯坦布尔患者对医药监管和补偿制度的看法
Emel Mashaki Ceyhan,Stuart Walker,Sam Salek
Emel Mashaki Ceyhan
Introduction: The aim of this study was to explore patients' knowledge and perspectives in Istanbul, Turkey about the pharmaceutical regulatory review and reimbursement processes with respect to patients' access to new me...
How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement [0.03%]
制药行业是如何构建儿科药物研发体系的？现有的儿科结构模型及对机构优化的建议
Thomas Severin,Solange Corriol-Rohou,Christina Bucci-Rechtweg et al.
Thomas Severin et al.
Background: Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, wi...
On Innovation [0.03%]
论创新
Waldo H Belloso
Waldo H Belloso
Innovation has become an increasingly common topic in healthcare. Private companies, developers, payers, and regulators are devoting attention toward innovative products and processes as a crucial component of their interests in and occupat...